Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hang Ke
Institutions:
Zhejiang Provincial People's Hospital,
Hangzhou Medical College
Observed institutions:
OceanX Technology (China),
Zhejiang Provincial People's Hospital,
Hangzhou Medical College,
OceanX,
Keymed Biosciences Inc. (China)
ORCID:
0000-0001-7617-9332
Observed ORCID:
0000-0001-7617-9332
OpenAlex ID:
A5034660877
Works
29
Awards
1
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
2023
·
Hang Ke
, Faming Zhang
, et al.
·
Scientific Reports
·
27
PDF
FK506-binding proteins: Emerging target and therapeutic opportunity in multiple tumors
2025
·
Hang Ke
, Zihan Chen
, et al.
·
International Journal of Biological Macromolecules
·
9
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
2024
·
Tao Yang
, Hang Ke
, et al.
·
Scientific Reports
·
8
PDF
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
2024
·
Hang Ke
, Tao Yang
, et al.
·
Scientific Reports
·
4
Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications
2022
·
Xiaoyu An
, Henry Li
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Abstract 2980: HX009, a first-in-class PD1xCD47 BsAb, demonstrated anti-AML activity in PDX models
2023
·
Xiaoyu An
, Jinping Liu
, et al.
·
Cancer Research
·
1
HX111, a FIC OX40-mAb-VC-MMAE for oncology, is exploited for POC investigation as a potential T-cell depleting candidate for autoimmunity
2026
·
Hang Ke
, Tao Yang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
OX40 could potentially be a novel causal oncogenic driver for certain T cell lymphoma
2026
·
Tao Yang
, Hang Ke
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
HX011-dFc, a novel OX40-mAb with silenced Fc, as a potential T-cell depletory candidate for the treatment of autoimmune diseases
2026
·
Tao Yang
, Hang Ke
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Pharmacological targeting of FKBPL with rapamycin sensitizes triple-negative breast cancer to ferroptosis
2026
·
Rongxue Li
, Hang Ke
, et al.
·
International Journal of Biological Macromolecules
Abstract 6949: A novel multi-modal PD-L1-ADC could be a potential BIC candidate treatment for pan-solid tumors with enhanced tumor-specificity
2026
·
Tao Yang
, Hang Ke
, et al.
·
Cancer Research
Abstract 5549: Non-clinical modeling the therapeutic window of HX044, a novel CTLA4xCD47 BsAb
2026
·
Hang Ke
, Zihan Xu
, et al.
·
Cancer Research
Abstract 4448: 3D-tumor organoid, over 2D-cell, is more predictive of in vivo anti-cancer pharmacology in assessing ADC candidates
2026
·
Tao Yang
, Jun Zhou
, et al.
·
Cancer Research
Abstract 6536: A novel multi-modal PD-L1xVEGF-ADC, HX116, could be a new potent candidate treatment for pan-solid tumors
2026
·
Hang Ke
, Tao Yang
, et al.
·
Cancer Research
HX111, a FIC OX40-mAb-VC-MMAE ADC for the treatment of lymphoma
2025
·
Tao Yang
, Hang Ke
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Exploration of sarcoma-associated OX40-expression using HX111, a novel FIC OX40-MaB-VC-MMAE-ADC, to treat OX40+ sarcoma
2025
·
Lu Xie
, Tao Yang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 6026: HX016-9, a novel PD1xVEGF BsAb, as a new candidate treatment of solid tumors
2025
·
Hang Ke
, Tao Yang
, et al.
·
Cancer Research
Abstract 3134: Preclinical anti-glioblastoma pharmacology of HX301, a novel CSF-1R inhibitor
2025
·
Tao Yang
, Hang Ke
, et al.
·
Cancer Research
Abstract 6076: Non-clinical pharmacology of HX044, a novel FIC CTLA4xCD47 bi-specific antibody
2025
·
Hang Ke
, Tao Yang
, et al.
·
Cancer Research
Abstract 4788: Discovery of HX035, an OX40-bi-epitope bi-specific antibody (BsAb), for the treatment of inflammatory/autoimmune diseases
2025
·
Hang Ke
, Tao Yang
, et al.
·
Cancer Research
Abstract 638: Discovery of HX016-7, a novel PD-L1 x VEGF BsAb, as a new candidate treatment of solid tumors
2025
·
Hang Ke
, Tao Yang
, et al.
·
Cancer Research
Abstract 2262: Genomic profiling of leukemic cell lines, responders vs. non-responders to Narazaciclib (HX301 or ON123300), a novel kinase inhibitor with activity against CSF1R and FLT3
2024
·
Jia Xue
, Tao Yang
, et al.
·
Cancer Research
Abstract 7161: Preclinical pharmacology modeling (pharmacokinetics/efficacy) of narazaciclib (HX301 or ON123300) to predict its clinical effective dose
2024
·
Tao Yang
, Hang Ke
, et al.
·
Cancer Research
543 Cis-binding/blockade of CD47 by CD47xPD1 BsAb HX009 enhanced PD1 blockade induced T-cell activation
2023
·
Hang Ke
, Cen Chen
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy
2023
·
Hang Ke
, Faming Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
29
Citation count:
51
H-index:
4
I10-index:
1
Year
Topic
Type